research tirzepatide Dual Agonist (GLP-1/GIP) Tirzepatide 10mg — GLP-1/GIP Dual-Agonist
Description
Months 7-12: Continued weight loss approaching 15% or more for semaglutide users and 20%+ for tirzepatide users
Can Semaglutide Interact with Other Medications
Research examining metabolic benefits of GLP-1 receptor agonists in patients with coexisting type 2 diabetes and autoimmune thyroid disease has shown that these medications remain effective for glycemic control and weight management in this population
It is important to note that while subcutaneous administration means absorption is not affected by altered gastrointestinal anatomy, patients may experience more pronounced gastrointestinal side effects
Compounding is the practice of formulating a copy of a commercial, brand-name medication to use in its place
